Found: 1
Select item for more details and to access through your institution.
P-224: Pomalidomide, bortezomib, and dexamethasone after 1 prior line of therapy in relapsed or refractory multiple myeloma (RRMM): A safety subanalysis of the phase 3 OPTIMISMM trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S163, doi. 10.1016/S2152-2650(21)02351-X
- By:
- Publication type:
- Article